Oklo shares fell 5% in Tuesday trading, another move in a volatile stretch for the advanced-nuclear developer as investors re-priced risk around commercialization and insider activity.
Jacob DeWitte, Oklo’s chief executive, has been at the center of that pressure: insiders sold roughly $35.1 million of stock over the past 90 days, about $14 million of it tied to DeWitte. The company’s shares were trading near $55.88, down roughly 22% year to date after Tuesday’s drop and off about 24.11% over the past week, though the stock is still up 41% over the past year and 459% over five years from its October 2025 low-to-high swing.
The headline numbers are blunt. Oklo remains pre-revenue while targeting first commercial power at Idaho National Laboratory in late 2027 to early 2028. Its most recent public filings show a string of losses — a $33.1 million net loss in the May 12 Q1 report versus $9.8 million a year earlier and an EPS of -$0.19 that met expectations — and another disclosed net loss of $73.6 million in its last reported quarter against $275.3 million in cash. The Q1 release also provoked a market reaction: shares tumbled about 10.84% in after-hours trading following the report.
Analysts and models give widely different roadmaps for the stock. A 24/7 Wall St. price target sits at $98.78, implying roughly 76.77% upside from the current price and carrying a buy rating at 50% confidence. JPMorgan holds a Neutral rating with an $83 target, while Tigress Financial has a Buy and a $130 target. Wolfe Research opened coverage at Peer Perform, flagging valuation, execution risk and a long commercialization timeline.
Oklo’s balance sheet and capital moves complicate the picture. The company says it has roughly $2.54 billion in liquidity after a $1.2 billion equity raise, and it launched a $1 billion at-the-market program in May. Those steps, designed to fund development, have also fed dilution concerns that weigh on sentiment despite the cash buffer.
Regulatory and technical milestones sit on a near-term calendar that investors say will determine whether concerns are overblown. The Nuclear Regulatory Commission approved Oklo’s Principal Design Criteria for the Aurora powerhouse on an accelerated schedule on May 6, 2026 — a regulatory win critics had expected to take longer. A criticality milestone scheduled for July 4, 2026 at the Groves Isotopes Test Reactor is now being watched as a potential validation of Oklo’s fast-fission approach.
Market interest is not purely speculative: Oklo reports a customer pipeline of about 14 gigawatts anchored by hyperscalers and data-center operators, including Switch, Equinix, Meta Platforms and NVIDIA, who have publicly signaled interest in new power sources for AI workloads. That demand case is the commercial upside investors hope to capture if the technology and licensing path hold.
But the tension is real. Insider selling has been heavy even as the company piles up milestones; an equity raise and an active ATM program increase the risk of dilution; and the sector has seen a broader unwind after parabolic gains earlier in the cycle. A popular forum post summed up the skeptics’ view bluntly, arguing that companies in the space lack working prototypes or concrete concepts — a point echoed in Wolfe Research’s initiation note.
Oklo’s immediate path is concrete: hit regulatory and reactor milestones, move from prototype demonstration toward commercial commissioning at Idaho National Laboratory, and show costs and timelines that reassure customers and analysts. The clearest near-term test is the July 4 criticality run at Groves — if it validates the fast-fission design, the narrative will shift from execution risk to deployment; if it fails, Oklo’s stock and credibility could face another leg down.
